Bioavailability alendronic acid ingestion in women is 0.7% at a dosage ranging from 5 to 40 mg in the fasting two hours immediately before breakfast. When administered in men (0.6%), it corresponds approximately to the indicator in women. Bioavailability is reduced by 40% when taking the period from 30 minutes to 1 hour before breakfast. After drinking coffee and orange juice reduced bioavailability by approximately 60%. Alendronic acid binding to serum proteins is about 78%. The drug is distributed in soft tissues, and then rapidly redistributed masteron propionate to bone, where it is fixing or excreted in the urine. The concentration of drug in blood plasma after oral administration in a therapeutic dose is below the potential measurement limit (<5 ng / ml). No biotransformation. Excretion of the drug is carried out in an unmodified form and is characterized by a rapid decrease in plasma drug concentration and very slow release of the bone.
Treatment of postmenopausal osteoporosis,
osteoporosis resulting from the use of drugs glyukokortikosteroinyh.
- hypersensitivity to any component of the drug;
- stricture or achalasia of the esophagus and other conditions that lead to slow progress on the esophagus food;
- the inability of the patient to stand or sit upright for at least 30 minutes;
- severe renal impairment (creatinine clearance less than 35 mL / min);
- Serious disturbances of mineral metabolism;
- diseases of the masteron propionate gastrointestinal tract in the acute phase (dysphagia, esophagitis, gastritis, duodenitis, gastric ulcer and 12 duodenal ulcer), hypovitaminosis .
Pregnancy and lactation
Pregnancy and lactation are contraindications to the use of the drug Tevanat.
Dosage and administration
To ensure proper absorption of the drug and reduce the risk of side effects should strictly observe the following recommendations for the use and dosage of the drug.
The drug Tevanat taken orally one tablet (10 mg), 1 per day.
Tablets are taken as a whole, in the morning on an empty stomach drinking a glass of water for at least 30 minutes before the first meal, drink or other use. medicaments. Wash down the drug only plain water because other drinks (including mineral water), food and some medicines can reduce the absorption Tevanata. Tablets should not be chewed or dissolve.
After taking the drug the patient must remain upright body position (sitting or standing) for at least 30 min. You can not take the medication at bedtime or before the morning masteron propionate rise from the bed.
Side effects Frequent (not less than 1/100, less than 1/10) From the gastrointestinal tract : stomach pain, indigestion, acid regurgitation, nausea, constipation, diarrhea, dysphagia, flatulence, gastritis, gastric ulcer, ulceration of the esophageal mucosa . On the part of the muscle, bone and connective tissue : bone, muscle and joint pain, muscle cramps. nervous system :. headache Infrequent (at least 1/1000, less than 1/100) Common : rash, pruritus, erythema. From the gastrointestinal tract : nausea, vomiting, gastritis, esophagitis, esophageal erosions, melena. Rare (not less than 1/10000, less than 1/1000)General : hypersensitivity reactions including urticaria and swelling angionevroticheky; transient symptoms similar with the symptoms of the disease in the acute phase (myalgia, malaise and rarely fever), usually at the beginning of treatment; rash with photosensitivity; Symptomatic hypocalcemia is usually associated with predisposing conditions. On the part of the gastrointestinal tract :. esophageal stricture, ulceration of the oropharynx, perforation, ulcers, bleeding in the upper gastrointestinal tract, although a causal relationship has not been established part of the vision : uveitis, scleritis, episcleritis. from the muscles and bones :. osteonecrosis have been reported osteonecrosis of the jaw in patients taking bisphosphonates. Most of the messages concerns of cancer patients, but such cases have also been reported in patients who were on treatment for osteoporosis. It has been reported about the individual cases of severe skin reactions, including masteron propionatesyndrome and toxic epidermal necrolysis.
In case of overdose may develop hypocalcemia, hypophosphatemia, and adverse reactions from the gastrointestinal tract: diarrhea, heartburn, esophagitis and erosive and ulcerative lesions gastrointestinal tract. Treatment : Milk or antacids to bind alendronate. Due to the risk of oesophageal irritation should not cause